Phase 3 randomized <scp>COMMODORE</scp> 2 trial: Crovalimab versus eculizumab in patients with <scp>paroxysmal nocturnal hemoglobinuria</scp> naive to complement inhibition
Alexander Röth(University of Duisburg-Essen), Bing Han(St. Michael's Hospital), Je‐Hwan Lee(Ulsan College), Martin Höglund(Uppsala University), Chattree Hantaweepant(Siriraj Hospital), Teresita Dumagay(Philippine General Hospital), Guangsheng He(Jiangsu Province Hospital), Sasha Sreckovic, Anna Gayà(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Sammy Chebon(Roche (Switzerland)), Hongyan Tong(First Affiliated Hospital Zhejiang University), Simon Buatois(Roche (Switzerland)), Jun Ho Jang(Samsung Medical Center), Antonio M. Risitano(European Society for Blood and Marrow Transplantation), Jun‐ichi Nishimura(The University of Osaka), Chatree Chai‐Adisaksopha(Chiang Mai University), Ponlapat Rojnuckarin(Chulalongkorn University), Naoshi Obara(University of Tsukuba Hospital), Brittany Gentile(Acentech (United States)), Andrés Brodsky(Universidad de Buenos Aires), Pontus Lundberg(Roche (Switzerland)), Leigh Beveridge, Roberta Demichelis‐Gómez(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Zenghua Lin(Nantong University), Fernando Silva(Centro Hospitalar do Baixo Vouga), Xiaoqin Wang(AstraZeneca (Japan)), Jing Sun(Qiqihar University), Richard J. Kelly(University of Leeds)
Cited by 46
Related Papers
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
|New England Journal of Medicine|2014|3.5k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Genome sequence and genetic diversity of the common carp, Cyprinus carpio
|Nature Genetics|2014|677